Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 23:384:e076316.
doi: 10.1136/bmj-2023-076316.

The estimands framework: a primer on the ICH E9(R1) addendum

Affiliations

The estimands framework: a primer on the ICH E9(R1) addendum

Brennan C Kahan et al. BMJ. .

Abstract

Estimands can be used in studies of healthcare interventions to clarify the interpretation of treatment effects. The addendum to the ICH E9 harmonised guideline on statistical principles for clinical trials (ICH E9(R1)) describes a framework for using estimands as part of a study. This paper provides an overview of the estimands framework, as outlined in the addendum, with the aim of explaining why estimands are beneficial; clarifying the terminology being used; and providing practical guidance on using estimands to decide the appropriate study design, data collection, and estimation methods. This article illustrates how to use the estimands framework by applying it to an ongoing trial in emergency bowel surgery. Estimands can be a useful way of clarifying the exact research question being evaluated in a study, both to avoid misinterpretation and to ensure that study methods are aligned to the overall study objectives.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at https://www.icmje.org/disclosure-of-interest/ and declare: support from the UK Medical Research Council and the NIHR for the submitted work. BCK and SC declare grant funding (payable to employing institutions) from the MRC-NIHR Trials Methodology Research Partnership. BCK and ME declare grant funding (payable to employing institutions) from the NIHR for the FLO-ELA trial. TPM declares consultancy fees from Bayer Healthcare Pharmaceuticals, Alliance Pharmaceuticals, Gilead Sciences, and Kite Pharma; declares conference attendance and travel paid for as an invited speaker at the 2023 European Society for Blood and Marrow Transplantation conference; and is an independent member of the data and safety monitoring board for the FLO-ELA trial. All other authors declare no conflicts of interest.

Figures

Fig 1
Fig 1
Different strategies regarding intercurrent events. In this example, a randomised trial compares intervention with control to understand how outcomes differ at month 2. However, one participant stops treatment before month 2 (ie, an intercurrent event). The figure shows what happens to this participant under each intercurrent event strategy. Under a composite strategy, investigators have decided to assign a score of 0 to any participant who experienced an intercurrent event. Under a while-on-treatment strategy, because the participant experienced an intercurrent event before month 2, their month 1 score of 3 is used in place of their month 2 score. Under a hypothetical strategy, the participant’s outcome that would have occurred had they continued treatment at month 2 is used (here, it is a value of 9); but in practice, this value will not be known and so must be estimated. M=month

References

    1. Edwards MR, Forbes G, Walker N, et al. FLO-ELA investigators . Fluid Optimisation in Emergency Laparotomy (FLO-ELA) Trial: study protocol for a multi-centre randomised trial of cardiac output-guided fluid therapy compared to usual care in patients undergoing major emergency gastrointestinal surgery. Trials 2023;24:313. 10.1186/s13063-023-07275-3 - DOI - PMC - PubMed
    1. Sedgwick P. Intention to treat analysis versus per protocol analysis of trial data. BMJ 2015;350:h681. 10.1136/bmj.h681 - DOI - PubMed
    1. Fergusson D, Aaron SD, Guyatt G, Hébert P. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ 2002;325:652-4. 10.1136/bmj.325.7365.652 - DOI - PMC - PubMed
    1. Kahan BC, White IR, Edwards M, Harlay MO. Using modified intention-to-treat as a principal stratum estimator for failure to initiate treatment. Clin Trials 2023;20:269-75. 10.1177/17407745231160074 - DOI - PMC - PubMed
    1. European Medicines Agency. ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. 2020. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e9-r1-ad....